Umair Munawar

Umair Munawar

Auto-generated profile, based on publicly available information

Umair Munawar

Department of Internal Medicine II, University Hospital Würzburg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2019 in Haematologica
Verified
Journal Article
Open access
PDF file
SBSantiago Barrio
Santiago Barrio
UMUmair Munawar
Umair Munawar
YZYuan Xiao Zhu
Yuan Xiao Zhu
NGNicola Giesen
Nicola Giesen
CSChang-Xin Shi
Chang-Xin Shi
KKK. Martin Kortüm
K. Martin Kortüm

18 October 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
MVMatteo Claudio Da Vià
Matteo Claudio Da Vià
Antonio Giovanni SolimandoAntonio Giovanni Solimando
Antonio Giovanni Solimando
AGAndoni Garitano-Trojaola
Andoni Garitano-Trojaola
SBSantiago Barrio
Santiago Barrio
UMUmair Munawar
Umair Munawar
KKK. Martin Kortüm
K. Martin Kortüm
Combined MEK‐BRAF inhibition is a well‐established treatment strategy in BRAF‐mutated cancer, most prominently in malignant melanoma with durable responses being achieved through this targeted therapy. However, a subset of patients face primary unresponsiveness despite presence of the activating mutation at position V600E, and others acquire resistance under treatment. Underlying resistance mechanisms are largely unknown, and diagnostic tests to predict tumor response to BRAF‐MEK inhibitor treatment are unavailable. Multiple myeloma represents the second most common hematologic malignancy, and point mutations in BRAF are detectable in about 10% of patients. Targeted inhibition has been successfully applied, with mixed responses observed in a substantial subset of patients mirroring the widespread spatial heterogeneity in this genomically complex disease. Central nervous system (CNS) involvement is an extremely rare, extramedullary form of multiple myeloma that can be diagnosed in less than 1% of patients. It is considered an ultimate high‐risk feature, associated with unfavorable cytogenetics, and, even with intense treatment applied, survival is short, reaching less than 12 months in most cases. Here we not only describe the first patient with an extramedullary CNS relapse responding to targeted dabrafenib and trametinib treatment, we furthermore provide evidence that a point mutation within the capicua transcriptional repressor (CIC) gene mediated the acquired resistance in this patient. Key Points. BRAF mutations constitute an attractive druggable target in multiple myeloma. This is the first genomic dissection of the central nervous system involvement in a multiple myeloma patient harboring a druggable BRAFV600E mutation. Deep genomic characterization of the extramedullary lesion prompted a personalized therapeutic approach. Acquisition of CIC mutation confers a mechanism of BRAF‐MEK inhibitor drug resistance in multiple myeloma. The in silico interrogation of the CoMMpass clinical study revealed 10 patients with somatic mutations of CIC and its downregulation at gene expression level in multiple myeloma. CIC gene silencing decreases the sensitivity of multiple myeloma cells to BRAF‐MEK inhibition in vitro. The correlation between CIC downregulation and ETV4/5 nuclear factor expression in multiple myeloma BRAF‐mutant cells is shown for the first time. CIC mutation, its downregulation, and the related downstream effect on MMP24 support disseminative potential providing new clues in the extramedullary biology definition.

4 November 2021 in Blood
Verified
Journal Article
Open access
PDF file
LHLarissa Haertle
Larissa Haertle
SBSantiago Barrio
Santiago Barrio
UMUmair Munawar
Umair Munawar
SHSeungbin Han
Seungbin Han
XZXiang Zhou
Xiang Zhou
KKK. Martin Kortüm
K. Martin Kortüm
Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy. Patients respond well to initial treatment with IMiDs, but virtually all patients develop drug resistance over time, and the underlying mechanisms are poorly understood. We identified an as yet undescribed DNA hypermethylation in an active intronic CRBN enhancer. Differential hypermethylation in this region was found to be increased in healthy plasma cells, but was more pronounced in IMiD-refractory MM. Methylation significantly correlated with decreased CRBN expression levels. DNA methyltransferase inhibitor (DNTMi) in vitro experiments induced CRBN enhancer demethylation, and sensitizing effects on lenalidomide treatment were observed in 2 MM cell lines. Thus, we provide first evidence that aberrant CRBN DNA methylation is a novel mechanism of IMiD resistance in MM and may predict IMiD response prior to treatment.

25 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LHLarissa Haertle
Larissa Haertle
SBSantiago Barrio
Santiago Barrio
UMUmair Munawar
Umair Munawar
SHSeungbin Han
Seungbin Han
XZXiang Zhou
Xiang Zhou
KKK. Martin Kortüm
K. Martin Kortüm
Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in multiple myeloma. We recently described the first in-patient point mutations affecting the 20S subunit PSMB5 underlying PI resistance. Notably, in vivo, the incidence of mutations in PSMB5 and other proteasome encoding genes is too low to explain the development of resistance in most of the affected patients. Thus, additional genetic and epigenetic alterations need to be explored. Experimental Design: We performed DNA methylation profiling by Deep Bisulfite Sequencing in PSMB5, PSMC2, PSMC5, PSMC6, PSMD1, and PSMD5, a subset of proteasome subunits that have hitherto been associated with PI resistance, recruited from our own previous research, the literature, or a meta-analysis on the frequency of somatic mutations. Methylation was followed up on gene expression level and by dual-luciferase reporter assay. The KMS11 cell line served as a model to functionally test the impact of demethylating agents. Results: We identified PSMD5 promoter hypermethylation and subsequent epigenetic gene silencing in 24% of PI refractory patients. Hypermethylation correlated with decreased expression and the regulatory impact of this region was functionally confirmed. In contrast, patients with newly diagnosed multiple myeloma, along with peripheral blood mononuclear cells and CD138+ plasma cells from healthy donors, generally show unmethylated profiles. Conclusions: Under the selective pressure of PI treatment, multiple myeloma cells acquire methylation of the PSMD5 promoter silencing the PSMD5 gene expression. PSMD5 acts as a key orchestrator of proteasome assembly and its downregulation was described to increase the cell's proteolytic capacity. PSMD5 hypermethylation, therefore, represents a novel mechanism of PI tolerance in multiple myeloma.

5 September 2019 in Blood
Verified
Journal Article
Closed access
PDF file
UMUmair Munawar
Umair Munawar
LRLeo Rasche
Leo Rasche
NMNicole Müller
Nicole Müller
CVCornelia Vogt
Cornelia Vogt
MVMatteo Claudio Da Vià
Matteo Claudio Da Vià
SBSantiago Barrio
Santiago Barrio

10 September 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
SNSven Neubert
Sven Neubert
UMUmair Munawar
Umair Munawar
JMJulia Mersi
Julia Mersi
JNJulia Noderer
Julia Noderer
SNSilvia Nerreter
Silvia Nerreter
JWJohannes M. Waldschmidt
Johannes M. Waldschmidt